CORC

在结果中检索

CORC

浏览/检索结果: 共39条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
The EMR-rural project: key techniques and devices’ development for rural environmental monitoring and remediation in China 期刊论文
Environmental Sciences Europe, 2020, 卷号: 32, 期号: 1, 页码: 72
作者:  Chen,Zhongli;  Shao,Ying;  He,Miao;  Liang,Jialiang;  Jiang,Yanxue
收藏  |  浏览/下载：10/0  |  提交时间：2020/05/18
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun
收藏  |  浏览/下载：58/0  |  提交时间：2019/12/05
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial 期刊论文
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 卷号: 4, 期号: 2
作者:  Li, Jun;  Jia, Jidong;  Hou, Jin Lin;  Mohamed, Rosmawati;  Duan, Zhongping
收藏  |  浏览/下载：44/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：46/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：37/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：39/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：30/0  |  提交时间：2019/12/05
Quercetin-3-O--L-rhamnopyranoside derived from the leaves of Lindera aggregata (Sims) Kosterm. evokes the autophagy-induced nuclear factor erythroid 2-related factor 2 antioxidant pathway in human umbilical vein endothelial cells 期刊论文
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2019, 卷号: 43, 期号: 1, 页码: 461-474
作者:  Han, Haote;  Xu, Bo;  Amin, Awais;  Li, Hongliang;  Yu, Xiuying
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/11
Quercetin‑3‑O‑α‑L‑rhamnopyranoside derived from the leaves of Linderaaggregata (Sims) Kosterm. evokes the autophagy‑induced nuclear factor erythroid2‑related factor 2 antioxidant pathway in human umbilical vein endothelial cells 期刊论文
International Journal of Molecular Medicine, 2019, 期号: 1
作者:  Haote Han;  Bo Xu;  Awais Amin;  Hongliang Li;  Xiuying Yu
收藏  |  浏览/下载：5/0  |  提交时间：2019/12/11

©版权所有 ©2017 CSpace - Powered by CSpace